About the job
Axsome Therapeutics focuses on developing therapies for central nervous system (CNS) disorders. The company’s neuroscience portfolio includes FDA-approved treatments for major depressive disorder, narcolepsy-related excessive daytime sleepiness, obstructive sleep apnea, and migraine. Several late-stage development programs target a broad range of severe neurological and psychiatric conditions.
Axsome aims to address significant challenges in brain health, with the goal of improving outcomes for patients and their families. Over 150 million people in the United States are affected by these conditions, and the company’s work centers on bridging gaps in care.
Learn more at www.axsome.com.

